retatrutide phase 2 trial type 2 diabetes weight loss 2024 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide: A Triple Agonist Shaping

For one study (SURPASS-2), we used data both from the journal publication [25] and from a conference abstract [24]

This increased medical attention could lead to a higher likelihood of their eye problems being detected and treated, which is what the study measured, creating the appearance of increased risk. Thirdly, the actual events were very small less than 0.2% so despite statistical adjustment results may not be accurate, he added

In addition, the GLP-1 can inhibit postprandial gastric emptying and reduce gastric acid secretion, inhibit gastric and duodenal peristalsis by inhibiting vagus nerve, and increase the pressure of pylorus, thus reducing appetite, causing a reduction in body weight and participating in the so-called ileal braking effect (35)

Thats where the right supplements come in

It is less potent than injectable agents but may be appropriate for patients who cannot tolerate or access injectable therapies

We monitor your progress with regular labs and adjust your protocol as your body composition and hormone levels change